Autor: |
Muhammad Umer Siddiqui, Omar Yacob, Joey Junarta, Ahmed K. Pasha, Farouk Mookadam, Mamas A. Mamas, David L. Fischman |
Jazyk: |
angličtina |
Rok vydání: |
2022 |
Předmět: |
|
Zdroj: |
BMC Cardiovascular Disorders, Vol 22, Iss 1, Pp 1-9 (2022) |
Druh dokumentu: |
article |
ISSN: |
1471-2261 |
DOI: |
10.1186/s12872-022-02651-4 |
Popis: |
Abstract Background With advancements in cancer treatment, the life expectancy of oncology patients has improved. Thus, transcatheter aortic valve replacement (TAVR) may be considered as a feasible option for oncology patients with severe symptomatic aortic stenosis (AS). We aim to evaluate the difference in short- and long-term all-cause mortality in cancer and non-cancer patients treated with TAVR for severe AS. Methods Medline, PubMed, and Cochrane Central Register of Controlled Trials were searched for relevant studies. Patients with cancer who underwent treatment with TAVR for severe AS were included and compared to an identical population without cancer. The primary endpoints were short- and long-term all-cause mortality. Results Of 899 studies included, 8 met inclusion criteria. Cancer patients had significantly higher long-term all-cause mortality after TAVR when compared to patients without cancer (risk ratio [RR] 1.43; 95% confidence interval (CI) 1.26–1.62; P |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|